AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Protagonist Therapeutics to Present at Investment Bank Conferences in September 2025
ByAinvest
Tuesday, Aug 26, 2025 4:16 pm ET1min read
Protagonist Therapeutics, a biopharmaceutical company, will participate in several investment bank conferences in September 2025. CEO Dinesh V. Patel will give fireside chats at Citi's Biopharma Back to School Summit, H.C. Wainwright's Global Investment Conference, and BofA's World Medical Innovation Forum. A replay of the presentations will be available on the company's website for one year.
Protagonist Therapeutics, Inc., a biopharmaceutical company, has announced its participation in several key investment bank conferences in September 2025. CEO Dinesh V. Patel, Ph.D., will be present at Citi's 2025 Biopharma Back to School Summit, H.C. Wainwright's 27th Annual Global Investment Conference, and BofA's 11th Annual World Medical Innovation Forum.At Citi's Biopharma Back to School Summit, scheduled for September 2-3 in Boston, MA, Patel will engage in a fireside chat on Wednesday, September 3, at 9:45 A.M. ET. The event will be webcast and available for replay on the company's Investor Relations webpage [1].
Patel will also participate in a fireside chat at H.C. Wainwright's 27th Annual Global Investment Conference, taking place from September 8-10 in New York, NY. This event will feature Patel's talk on Tuesday, September 9, at 11:30 A.M. ET, also with a webcast available for replay [1].
At BofA's 11th Annual World Medical Innovation Forum, held from September 15-17 in Boston, MA, Patel will join a panel discussion titled "Immunology: Creating the next blockbuster in I&I" on Tuesday, September 16 [1].
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company with two novel peptides in advanced Phase 3 clinical development. Icotrokinra, a first-in-class investigational targeted oral peptide, is licensed to J&J Innovative Medicines, and Rusfertide, a mimetic of the natural hormone hepcidin, is being co-developed with Takeda Pharmaceuticals for the rare blood disorder polycythemia vera (PV) [1].
Interested parties can reach out to their respective conference representatives to arrange meetings with the Protagonist team. Replays of the presentations will be available on the Company's Investor Relations Events and Presentations webpage for one year following the event [1].
References:
[1] https://www.newswire.com/news/protagonist-therapeutics-to-participate-in-multiple-investment-bank-conferences
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet